Kilitch Drugs (India) Limited (KILITCH.BO)
INR 317.75
(-0.87%)
INR 317.75
(-0.87%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 316.46 Million INR | 42.59% |
| 2022 | 221.93 Million INR | 8.62% |
| 2021 | 204.31 Million INR | 38.02% |
| 2020 | 148.03 Million INR | 17.4% |
| 2019 | 126.09 Million INR | 33.37% |
| 2018 | 94.54 Million INR | 925.72% |
| 2017 | 9.21 Million INR | 34.54% |
| 2016 | 6.85 Million INR | 214.41% |
| 2015 | 2.17 Million INR | 21690.0% |
| 2014 | 10 Thousand INR | 0.0% |
| 2013 | - INR | 0.0% |
| 2012 | - INR | -100.0% |
| 2011 | 88.05 Million INR | -43.71% |
| 2010 | 156.44 Million INR | -63.61% |
| 2009 | 429.89 Million INR | 21.36% |
| 2008 | 354.24 Million INR | -16.96% |
| 2007 | 426.59 Million INR | 115.38% |
| 2006 | 198.06 Million INR | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 Q1 | - INR | -100.0% |
| 2023 Q3 | - INR | -100.0% |
| 2023 FY | 316.46 Million INR | 42.59% |
| 2023 Q4 | 316.46 Million INR | 0.0% |
| 2023 Q2 | 287.34 Million INR | 0.0% |
| 2022 Q4 | 221.93 Million INR | 0.0% |
| 2022 Q3 | - INR | -100.0% |
| 2022 Q1 | - INR | -100.0% |
| 2022 Q2 | 189.37 Million INR | 0.0% |
| 2022 FY | 221.93 Million INR | 8.62% |
| 2021 FY | 204.31 Million INR | 38.02% |
| 2021 Q1 | - INR | -100.0% |
| 2021 Q4 | 204.31 Million INR | 0.0% |
| 2021 Q2 | 175.69 Million INR | 0.0% |
| 2021 Q3 | - INR | -100.0% |
| 2020 FY | 148.03 Million INR | 17.4% |
| 2020 Q2 | 138.49 Million INR | 0.0% |
| 2020 Q4 | 148.03 Million INR | 0.0% |
| 2019 Q4 | 126.09 Million INR | 0.0% |
| 2019 FY | 126.09 Million INR | 33.37% |
| 2019 Q2 | 133.57 Million INR | 0.0% |
| 2018 Q4 | 94.54 Million INR | 0.0% |
| 2018 FY | 94.54 Million INR | 925.72% |
| 2017 FY | 9.21 Million INR | 34.54% |
| 2016 FY | 6.85 Million INR | 214.41% |
| 2015 FY | 2.17 Million INR | 21690.0% |
| 2014 FY | 10 Thousand INR | 0.0% |
| 2013 FY | - INR | 0.0% |
| 2012 Q4 | - INR | 0.0% |
| 2012 FY | - INR | -100.0% |
| 2012 Q2 | 1.04 Million INR | 0.0% |
| 2011 FY | 88.05 Million INR | -43.71% |
| 2010 FY | 156.44 Million INR | -63.61% |
| 2009 FY | 429.89 Million INR | 21.36% |
| 2008 FY | 354.24 Million INR | -16.96% |
| 2007 FY | 426.59 Million INR | 115.38% |
| 2006 FY | 198.06 Million INR | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| Ajanta Pharma Limited | 352.8 Million INR | 10.299% |
| Amrutanjan Health Care Limited | 17.28 Million INR | -1731.077% |
| Sigachi Industries Limited | 1.43 Billion INR | 77.878% |
| Bal Pharma Limited | 1.39 Billion INR | 77.338% |
| Ind-Swift Laboratories Limited | 166.21 Million INR | -90.394% |
| Medico Remedies Limited | 80.5 Million INR | -293.105% |
| Lasa Supergenerics Limited | 220.76 Million INR | -43.351% |
| Venus Remedies Limited | 413.3 Million INR | 23.43% |
| Sun Pharma Advanced Research Company Limited | 611.5 Million INR | 48.248% |
| Alpa Laboratories Limited | 52.46 Million INR | -503.193% |
| Nectar Lifesciences Limited | 6.35 Billion INR | 95.021% |
| Shilpa Medicare Limited | 9.37 Billion INR | 96.624% |
| Aarti Drugs Limited | 5.64 Billion INR | 94.392% |
| Lupin Limited | 29.21 Billion INR | 98.917% |
| Aurobindo Pharma Limited | 66.47 Billion INR | 99.524% |
| Zydus Lifesciences Limited | 8.04 Billion INR | 96.065% |
| Windlas Biotech Limited | 36.41 Million INR | -769.171% |
| Suven Life Sciences Limited | 7.09 Million INR | -4359.138% |
| Eris Lifesciences Limited | 27.81 Billion INR | 98.862% |
| Valiant Laboratories Limited | 767.08 Million INR | 58.744% |
| J. B. Chemicals & Pharmaceuticals Limited | 3.77 Billion INR | 91.62% |
| Solara Active Pharma Sciences Limited | 10.11 Billion INR | 96.871% |
| Ipca Laboratories Limited | 14.38 Billion INR | 97.8% |
| Bliss GVS Pharma Limited | 998.4 Million INR | 68.303% |
| Achyut Healthcare Limited | - INR | -Infinity% |
| Sun Pharmaceutical Industries Limited | 32.73 Billion INR | 99.033% |
| Bajaj HealthCare Limited | 3.32 Billion INR | 90.492% |
| RPG Life Sciences Limited | - INR | -Infinity% |
| Mankind Pharma Limited | 2.07 Billion INR | 84.725% |
| Laurus Labs Limited | 25.77 Billion INR | 98.772% |
| Piramal Pharma Limited | 47.1 Billion INR | 99.328% |
| Syncom Formulations (India) Limited | 724.86 Million INR | 56.342% |
| Torrent Pharmaceuticals Limited | 40.22 Billion INR | 99.213% |
| Alembic Pharmaceuticals Limited | 5.13 Billion INR | 93.833% |
| Glenmark Pharmaceuticals Limited | 12.3 Billion INR | 97.429% |
| Unichem Laboratories Limited | 2.47 Billion INR | 87.214% |
| Sequent Scientific Limited | 4.87 Billion INR | 93.511% |
| Novartis India Limited | 69.7 Million INR | -354.039% |
| Wanbury Limited | 1.16 Billion INR | 72.832% |
| Suven Pharmaceuticals Limited | 649.96 Million INR | 51.31% |
| Wockhardt Limited | 23.56 Billion INR | 98.657% |
| Themis Medicare Limited | 957.92 Million INR | 66.963% |
| Jagsonpal Pharmaceuticals Limited | 89.41 Million INR | -253.948% |
| Jubilant Pharmova Limited | 36.64 Billion INR | 99.136% |
| Glenmark Life Sciences Limited | 171.48 Million INR | -84.549% |
| Dr. Reddy's Laboratories Limited | 20.02 Billion INR | 98.419% |
| Divi's Laboratories Limited | 30 Million INR | -954.883% |
| NATCO Pharma Limited | 3.71 Billion INR | 91.475% |
| Gufic Biosciences Limited | 3.32 Billion INR | 90.494% |
| IOL Chemicals and Pharmaceuticals Limited | 327.6 Million INR | 3.399% |
| Ind-Swift Limited | 10.13 Billion INR | 96.879% |
| Procter & Gamble Health Limited | 95.6 Million INR | -231.03% |
| FDC Limited | 205.18 Million INR | -54.234% |
| Krebs Biochemicals & Industries Limited | 1.93 Billion INR | 83.639% |
| Granules India Limited | 13.15 Billion INR | 97.594% |
| Medicamen Biotech Limited | 308.17 Million INR | -2.691% |
| Alkem Laboratories Limited | 14.18 Billion INR | 97.769% |
| AstraZeneca Pharma India Limited | 45.98 Million INR | -588.237% |
| Biofil Chemicals and Pharmaceuticals Limited | 4.38 Million INR | -7110.412% |
| Brooks Laboratories Limited | 56.41 Million INR | -460.919% |
| Megasoft Limited | 1.47 Billion INR | 78.479% |
| ZIM Laboratories Limited | 1.08 Billion INR | 70.92% |
| Strides Pharma Science Limited | 25.16 Billion INR | 98.743% |
| Neuland Laboratories Limited | 953.89 Million INR | 66.824% |
| Morepen Laboratories Limited | 289.99 Million INR | -9.129% |
| Hikal Limited | 8.17 Billion INR | 96.129% |
| Indoco Remedies Limited | 6.71 Billion INR | 95.29% |
| Aarti Pharmalabs Limited | 2.85 Billion INR | 88.906% |
| Mangalam Drugs & Organics Limited | 984.92 Million INR | 67.869% |
| Hester Biosciences Limited | 2.44 Billion INR | 87.05% |